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httpcense.Abstract Background: Because the cost of inpatient care for pneumonia is up to 25 times greater
than that of outpatient care, CRP could be useful in deciding whether hospitalization is necessary.
Indeed, because of the wide number of clinical conditions associated with Hs-CRP levels, Hs-CRP
can never be diagnostic on its own and can only be interpreted at the bedside, in full knowledge of
all other clinical and pathologic results. However, it can then contribute powerfully to management,
just as recording of the patient’s temperature, an equally nonspeciﬁc parameter, is of great clinical
utility.
Aim of work: To evaluate the diagnostic and prognostic value of serum level of high sensitivity C
reactive protein in community acquired pneumonia.
Subjects and methods: This is a prospective study in which Hs-CRP was measured in 54 patients
admitted to chest department or respiratory I.C.U. in Abbasia Chest Hospital with a recently diag-
nosed community acquired pneumonia which is conﬁrmed clinically and radiological from January
2010 to June 2010 using Nephlometry method (Siemens Prospec).
Results: There was signiﬁcant correlation between serum Hs-CRP level and outcome of cases
(died or survived). The results showed a signiﬁcant correlation between serum Hs-CRP level and
need of I.C.U. admission, need of oxygen therapy, need of mechanical ventilation as well as a sig-
niﬁcant positive correlation between serum Hs-CRP level and length of hospital stay among sur-
vived patients.01001649587.
m (H.A. Haﬁz).
e Egyptian Society of Chest
g by Elsevier
of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
://dx.doi.org/10.1016/j.ejcdt.2013.05.011
302 H.A. Youssef et al.Conclusions: Hs-CRP has a signiﬁcant prognostic value in community acquired pneumonia and
can be used as a marker of severity.
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Pneumonia is deﬁned as inﬂammation and consolidation of the
lung tissue due to an infectious agent. Pneumonia that devel-
ops outside the hospital is considered community acquired
pneumonia (CAP). Pneumonia developing 72 h or more after
admission to hospital is called nosocomial, or hospital ac-
quired pneumonia [1].
Once a diagnosis of pneumonia has been made, the next
decision is whether or not to admit the patient to the hospital.
Now, more than ever, there is considerable pressure to treat as
many patients as possible at home [2]. Because the cost of inpa-
tient care for pneumonia is up to 25 times greater than that of
outpatient care [3].
The use of clinical rules or scoring systems to prompt early
referral to intensive care can signiﬁcantly reduce the incidence
of cardiac arrest, and probably mortality [4].
C reactive protein (CRP) was identiﬁed by Tilet and Fran-
cis in 1930 in the plasma of patients with pneumonia, and was
named for its ability to bind and precipitate the C-polysaccha-
ride of pneumococcus [5]. Following an acute phase stimulus,
values of CRP may increase 10,000 fold. Synthesis starts very
rapidly after a single stimulus with serum concentrations rising
up to 5 mg/L by approximately 6 h and peaking at approxi-
mately 48 h. The plasma half-life of CRP is approximately
19 h and is constant under all conditions of health and disease,
so that the sole determinant of circulating CRP concentration
is the synthesis rate [6].
CRP could be useful in deciding whether hospitalization
is necessary. Indeed, because of the wide number of clinical
conditions associated with Hs-CRP levels, Hs-CRP can
never be diagnostic on its own and can only be interpreted
at the bedside, in full knowledge of all other clinical and
pathologic results. However, it can then contribute power-
fully to management, just as recording of the patient’s tem-
perature, an equally nonspeciﬁc parameter, is of great
clinical utility [7].
Patients with higher Hs-CRP levels had longer duration of
fever; patients had longer hospital stay; and fewer patients
had recovered clinically or radiographically at follow-up
8 weeks after discharge. These ﬁndings suggest that Hs-CRP
could be used together with other clinical, radiographic,
and laboratory ﬁndings for the risk stratiﬁcation of patients
with pneumonia. Besides the usefulness as a diagnostic tool
for pneumonia, etiologic diagnosis, and outcome marker,
there could be some place for Hs-CRP in the follow-up of
pneumonia [8].Aim of work
To evaluate the diagnostic and prognostic value of serum level
of high sensitivity C-reactive protein in community acquired
pneumonia.Subjects and methods
This is a prospective study that included 54 patients admitted
to hospital with a recently diagnosed community acquired
pneumonia which is conﬁrmed clinically and radiological from
January 2010 to June 2010 after having their written informed
consent prior to participation in the study. Control group con-
sists of 10 healthy individuals with no signs or symptoms of
inﬂammatory process and no history of chronic illness. All
individuals of the control group were subjected to Hs-CRP as-
say using Nephlometry method (Siemens Prospec).
Hs-CRP is an in vitro diagnostic assay indented for the
quantitative determination of CRP in the human serum. Poly-
styrene particles coated with monoclonal antibodies to CRP
are agglutinated when mixed with samples containing CRP.
The intensity of the scattered light in the nephelometer de-
pends on the CRP content of the sample and therefore the
CRP concentration can be determined versus dilutions of a
standard of a known concentration [8].
Any conditions which may affect the serum level of Hs-
CRP including: COPD, bronchial asthma, coronary heart dis-
ease, rheumatoid arthritis, interstitial lung disease, rheumatic
fever, myocardial infarction, leprosy, malignancy, congestive
heart failure, blood diseases, allergic diseases, kidney diseases,
and different infectious diseases (tuberculosis, meningitis,
poliomyelitis, and infectious mononucleosis) were excluded.
Results
Table 1 shows that Hs-CRP was statistically signiﬁcantly high-
er in cases than control.
Tables 2 and 3 showed that there was a signiﬁcant correla-
tion between serum Hs-CRP level and outcome of cases (died
or survived). The results showed a signiﬁcant correlation be-
tween serum Hs-CRP level and need of I.C.U. admission.
The results in this study showed that there was a signiﬁcant
positive correlation between patient serum Hs-CRP level and
their score on CURB-65 scoring system.
The study showed a signiﬁcant positive correlation between
patient serum Hs-CRP level and length of hospital stay among
survived patients.
Discussion
Current guidelines agree that severity assessment is a pivotal
early step in the management of patients presenting with
CAP. There is, however, no uniform agreement on the opti-
mum severity assessment tool or an agreed deﬁnition of the
term ‘severe pneumonia’ [9].
Pneumonia elicits a powerful inﬂammatory response. The
release of inﬂammatory mediators from activated mononu-
clear phagocyte cells constitutes an important part of the host
response to infection. Of these mediators, inteleukin-6 is a ma-
Table 1 Serum Hs-CRP level; statistical comparison between
patients’ group and control.
Type P Sig.
Case Control
N % N %
Hs-CRP level
<10 4 7.4 10 100 .001 HS
10–50 16 29.6 0 0
50–100 9 16.7 0 0
>100 25 46.3 0 0
Table 3 Correlations between Hs-CRP level and outcome
(died or survived) among patients’ group.
Died Survived P Sig.
N % N %
<10 mg/l 0 0 4 100 .001 HS
Hs-CRP level
<10 mg/l 0 0 4 100 .001 HS
10–50 mg/l 1 6.2 15 93.8
>50–100 mg/l 1 11.1 8 88.9
>100 mg/l 18 72 7 28
Total number 20 37 34 63
Table 4 Sensitivity for CAP prediction from the serum level
of Hs-CRP among patients’ group.
Diagnostic test Sensitivity (%) P Sig.
Cutoﬀ = 3.20 96.3 .001 HS
Table 5 Sensitivity and speciﬁcity for prediction of the
outcome (died or survived) for CAP patients by using the
serum level of Hs-CRP.
Diagnostic test Sensitivity (%) Speciﬁcity (%) P Sig.
Cutoﬀ = 108.5 85 85.3 .001 HS
Evaluation of diagnostic and prognostic value of high sensitivity C reactive protein (Hs-CRP) 303jor inducer of acute-phase proteins, including the C-reactive
protein (CRP).The early determination of serum concentra-
tions of CRP is a well-established laboratory test for the diag-
nosis and monitoring of different acute inﬂammatory
processes [10]. Over the last few years, a new high sensitive
immunoassay technique for the measurement of CRP has been
introduced in clinical immunology laboratories. Such new
technology is called high sensitivity CRP (Hs-CRP) and is cur-
rently used for routine CRP assessment [11].
Regarding serum level of Hs-CRP the mean was 91.68 mg/l
with SD±73.53 among cases and the mean was 0.72 mg/l with
SD ±0.32 among controls and the difference was found to be
statistically highly signiﬁcant. Mustafa et al. [12] included 160
patients with conﬁrmed CAP the Mean Hs-CRP was
135.7 mg/l SD ±48.6 and Mu¨ller and Stephan [13] included
545 patients with conﬁrmed CAP the mean Hs-CRP was
103.4 mg/l SD ±89.9.
As regards the need of I.C.U. admission in this study, thirty
one patients of the included patients needed ICU admission
representing (57.4%) as shown in Table 2; twenty three of
them had serum Hs-CRP level more than 100 mg/L and 23 pa-
tients were not in need of ICU admission representing
(42.6%); only two of them had serum Hs-CRP level more than
100 mg/l. These results agree with the results of James et al.
[14] who showed that patients with low admission Hs-CRP lev-
els <100 mg/L effectively exclude severe community-acquired
pneumonia; Hs-CRP <100 mg/L provide a good negative pre-
dictive value comparable with CURB-65 scoring system for
pneumonia severity. Clyne and Olshaker [15] showed that
Hs-CRP had been proved as a screening device for inﬂamma-
tion and a marker for disease severity.
Twenty patients representing 37% of the included patients
died as shown in Table 3, 18 of them had serum Hs-CRP level
more than 100 mg/l. These results were in agreement with the
results of Seppa et al. [16] who showed that higher Hs-CRP
levels appear to predict severity of illness, Hs-CRP level above
100 mg/L is a marker independently associated with a higher
risk of death in patients with lower respiratory tract infections.Table 2 Correlations between Hs-CRP level and need of I.C.U. ad
Hs-CRP level
<10 10–50
N % N %
Negative 4 100 13 81.3
Positive 0 0 3 18.7By using the ROC curve for disease prediction from the ser-
um level of Hs-CRP the area under the curve showing a cutoff
point of 3.20 mg/l with sensitivity 96.3% (P value <0.001)
(Table 4).
By using the ROC curve for prediction of the outcome (died
or survived) from the serum level of Hs-CRP the area under
the curve showing a cutoff point of 108.5 mg/l with sensitivity
85% and speciﬁcity 85.3% (P value <0.001) (Table 5). These
results were in agreement with the results of Almirall et al. [17]
who showed that serum CRP level could be used at the time of
diagnosis of CAP as a criterion of severity. In this respect, sen-
sitivity and speciﬁcity values for the best cut points in men
(106 mg/L) and women (110 mg/L) with a sensitivity of
80.5% and a speciﬁcity of 80.7%; Hs-CRP is a good marker
of CAP diagnosis, as well as useful for assessing its clinical
severity.
In conclusion, Hs-CRP has a signiﬁcant prognostic value in
community acquired pneumonia and can be used as a marker
of severity in these cases.mission among patients’ group.
P Sig.
>50–100 >100
N % N %
4 44.4 2 8 .001 HS
5 55.6 23 92
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